Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Hyung-Seung Jin"'
Publikováno v:
Experimental and Molecular Medicine, Vol 56, Iss 10, Pp 2113-2126 (2024)
Abstract Cancer immunotherapy aims to initiate or amplify immune responses that eliminate cancer cells and create immune memory to prevent relapse. Immune checkpoint inhibitors (ICIs), which target coinhibitory receptors on immune effector cells, suc
Externí odkaz:
https://doaj.org/article/9c333c08878043bf93cd76228a3caa8d
Autor:
Dong-hee Lee, Hyejin Ahn, Hye-In Sim, Eunji Choi, Seunghyun Choi, Yunju Jo, Bohwan Yun, Hyun Kyu Song, Soo Jin Oh, Kaori Denda-Nagai, Chan-Sik Park, Tatsuro Irimura, Yoon Park, Hyung-seung Jin
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-19 (2023)
Abstract Background Immunotherapy has significantly advanced cancer treatments, but many patients do not respond to it, partly due to immunosuppressive mechanisms used by tumor cells. These cells employ immunosuppressive ligands to evade detection an
Externí odkaz:
https://doaj.org/article/5a2155d0c9c541b7b2a52446c3747bb0
Autor:
Eun Young Jeon, Da‐som Choi, Seunghyun Choi, Ju‐young Won, Yunju Jo, Hye‐bin Kim, Youngmee Jung, Sang Chul Shin, Hophil Min, Hae Woong Choi, Myeong Sup Lee, Yoon Park, Justin J. Chung, Hyung‐seung Jin
Publikováno v:
Bioengineering & Translational Medicine, Vol 8, Iss 1, Pp n/a-n/a (2023)
Abstract Adoptive cell therapy (ACT) with antigen‐specific T cells is a promising treatment approach for solid cancers. Interleukin‐2 (IL‐2) has been utilized in boosting the efficacy of ACT. However, the clinical applications of IL‐2 in comb
Externí odkaz:
https://doaj.org/article/cb2daf617e7d480ab04c6bf1711ee83a
Autor:
Wenqing Jiang, Zhengyi Wang, Jaeho Jung, Hyunjoo Kim, Eunsil Sung, Jaehyoung Jeon, Youngkwang Kim, Shinai Lee, Yangmi Lim, Jonghwa Won, Uijung Jung, Hyung-Seung Jin, Gihoon You
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/f2416e2fe6da445a8a372f7dee52ac8d
Publikováno v:
Biomedicines, Vol 10, Iss 2, p 299 (2022)
Immune checkpoint inhibitor therapy has proven efficacy in a subset of colon cancer patients featuring a deficient DNA mismatch repair system or a high microsatellite instability profile. However, there is high demand for more effective biomarkers to
Externí odkaz:
https://doaj.org/article/9d8b50d4be71450a8b66619c00cc2c80
Publikováno v:
Pharmaceuticals, Vol 14, Iss 10, p 1053 (2021)
The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. MUC proteins contribute to the formation of the mucus barrier and thus have protective functions against infection. I
Externí odkaz:
https://doaj.org/article/800b039c41fc4000a3e674e919187830
Publikováno v:
Pharmaceuticals, Vol 14, Iss 3, p 200 (2021)
Tumors escape immune surveillance by inducing various immunosuppressive pathways, including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal antibodies (mAbs) blocking programmed cell death 1 (PD-1), programmed d
Externí odkaz:
https://doaj.org/article/e7f5f0ea03d646a6b197efce9ef2987f
Autor:
Eunsil Sung, Minkyung Ko, Ju-young Won, Yunju Jo, Eunyoung Park, Hyunjoo Kim, Eunji Choi, Ui-jung Jung, Jaehyoung Jeon, Youngkwang Kim, Hyejin Ahn, Da-som Choi, Seunghyun Choi, Youngeun Hong, Hyeyoung Park, Hanbyul Lee, Yong-Gyu Son, Kyeongsu Park, Jonghwa Won, Soo Jin Oh, Seonmin Lee, Kyu-pyo Kim, Changhoon Yoo, Hyun Kyu Song, Hyung-seung Jin, Jaeho Jung, Yoon Park
Publikováno v:
Molecular Therapy. 30:2800-2816
Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with other checkpoint inhibitors. Lymphocyte-activation gene 3 (LAG-3) is an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a56d0128b6f787ced7cc412d81543db9
https://doi.org/10.1016/j.ymthe.2022.05.003
https://doi.org/10.1016/j.ymthe.2022.05.003
Autor:
Yoon Park, Changhoon Yoo, Kyu-pyo Kim, Eun Kyung Choi, Hee Jin Lee, Inki Kim, Seong-Ho Kang, Dong-hee Lee, June Hyuck Kim, Da-som Choi, Minkyung Ko, Hyung-seung Jin
Containing Supplementary Figures S1 - S12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0d585a2c63625859bc4c28c0fd8b98
https://doi.org/10.1158/2326-6066.22543818.v1
https://doi.org/10.1158/2326-6066.22543818.v1
Autor:
Yoon Park, Changhoon Yoo, Kyu-pyo Kim, Eun Kyung Choi, Hee Jin Lee, Inki Kim, Seong-Ho Kang, Dong-hee Lee, June Hyuck Kim, Da-som Choi, Minkyung Ko, Hyung-seung Jin
Clinical trials are evaluating the efficacy of anti-TIGIT for use as single-agent therapy or in combination with programmed death 1 (PD-1)/programmed death-ligand 1 blockade. How and whether a TIGIT blockade will synergize with immunotherapies is not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03e96978365d9ce30d83ceaa2f8e5074
https://doi.org/10.1158/2326-6066.c.6550419.v1
https://doi.org/10.1158/2326-6066.c.6550419.v1